Brentuximab Vedotin (BV), an anti-CD30 antibody conjugated to monomethyl auristatin E (MMAE), has been highly effective against anaplastic large cell lymphoma (ALCL), some CD30+ peripheral T-cell lymphoma (PTCL) and classical Hodgkin lymphoma (cHL)[64,65]. The gene discussed is TNFRSF8; the disease is peripheral T-cell lymphoma, not otherwise specified.